SKIN: The Beauty Health Company Stock

by  •  • Comments Off on SKIN: The Beauty Health Company Stock

SIC 3841 – Surgical and Medical Instruments and Apparatus

Valuation
Market Cap ($M) 443.22
Enterprise Value ($M) 664.07
Book Value ($M) 63.30
Book Value / Share 0.51
Price / Book 7.00
NCAV ($M) -166.62
NCAV / Share -1.35
Price / NCAV -2.66

Profitability (mra)
Return on Invested Capital (ROIC) -0.11
Return on Assets (ROA) -0.08
Return on Equity (ROE) -0.55

Liquidity (mrq)
Quick Ratio 5.55
Current Ratio 6.57

Balance Sheet (mrq) ($M)
Current Assets 614.82
Assets 844.74
Liabilities 781.45
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 397.99
Operating Income -130.92
Net Income -100.12

Cash Flow Statement (mra) ($M)
Cash From Operations 21.75
Cash from Investing -31.51
Cash from Financing -37.45

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
04-05 13G/A Janus Henderson Group Plc 10.60 4.10
03-14 13D/A LCP Edge Holdco LLC 27.03 0.00
02-14 13G/A Luxor Capital Group, LP 6.50 24.22
02-13 13G/A Vanguard Group Inc 5.53 -24.00
02-09 13G/A Senvest Management, LLC 0.00 -100.00
01-10 13G/A Fmr Llc 12.79 32.24

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-05-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO
2024-03-12 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K
2023-11-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT
2023-08-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO S

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-05-10 1,392,869 1,717,181 81.11
2024-05-09 853,860 899,075 94.97
2024-05-08 378,197 446,902 84.63

(click for more detail)

Similar Companies
RSLS – ReShape Lifesciences Inc. SEPA – SEP Acquisition Corp.
SINT – Sintx Technologies, Inc. SLNO – Soleno Therapeutics, Inc.
SMLR – Semler Scientific, Inc.


Financial data and stock pages provided by
Fintel.io